Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy

Nature Reviews Clinical Oncology

Volumn 14, Issue 4, 2017, Pages 247-258

  Galluzzi, Lorenzo ^a,b,c,d,e,f   Pedro, José Manuel Bravo San ^b,c,d,e,f   Demaria, Sandra ^a   Formenti, Silvia Chiara ^a   Kroemer, Guido ^{b,c,d,e,f,g,h}  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GENISTEIN; HYDROXYCHLOROQUINE; HYDROXYCITRIC ACID; MELPHALAN; MITOXANTRONE; OXALIPLATIN; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; VORINOSTAT;

ADVANCED CANCER; AUTOPHAGY; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ACTIVATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; FIBROSARCOMA; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR MICROENVIRONMENT; FORECASTING; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

AUTOPHAGY; CLINICAL TRIALS AS TOPIC; FORECASTING; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84995370898     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.183     Document Type: Review

References (122)

1. Lamb, C. A., Yoshimori, T. & Tooze, S. A. The autophagosome: origins unknown, biogenesis complex. Nat. Rev. Mol. Cell Biol. 14, 759-774 (2013).
2. Menzies, F. M., Fleming, A. & Rubinsztein, D. C. Compromised autophagy and neurodegenerative diseases. Nat. Rev. Neurosci. 16, 345-357 (2015).
3. Green, D. R., Galluzzi, L. & Kroemer, G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 333, 1109-1112 (2011).
4. Kaur, J. & Debnath, J. Autophagy at the crossroads of catabolism and anabolism. Nat. Rev. Mol. Cell Biol. 16, 461-472 (2015).
5. Galluzzi, L., Pietrocola, F., Levine, B. & Kroemer, G. Metabolic control of autophagy. Cell 159, 1263-1276 (2014).
6. Fuchs, Y. & Steller, H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat. Rev. Mol. Cell Biol. 16, 329-344 (2015).
7. Galluzzi, L., Bravo-San Pedro, J. M., Blomgren, K. & Kroemer, G. Autophagy in acute brain injury. Nat. Rev. Neurosci. 17, 467-484 (2016).
8. Galluzzi, L. et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 22, 58-73 (2015).
9. Green, D. R. & Levine, B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell 157, 65-75 (2014).
10. Sica, V. et al. Organelle-specific initiation of autophagy. Mol. Cell 59, 522-539 (2015).
11. Efeyan, A., Comb, W. C. & Sabatini, D. M. Nutrient-sensing mechanisms and pathways. Nature 517, 302-310 (2015).
12. Farre, J. C. & Subramani, S. Mechanistic insights into selective autophagy pathways: lessons from yeast. Nat. Rev. Mol. Cell Biol. 17, 537-552 (2016).
13. Deretic, V., Saitoh, T. & Akira, S. Autophagy in infection, inflammation and immunity. Nat. Rev. Immunol. 13, 722-737 (2013).
14. Galluzzi, L. et al. Autophagy in malignant transformation and cancer progression. EMBO J. 34, 856-880 (2015).
15. Yue, Z., Jin, S., Yang, C., Levine, A. J. & Heintz, N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl Acad. Sci. USA 100, 15077-15082 (2003).
16. Takamura, A. et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 25, 795-800 (2011).
17. Wei, Y. et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 154, 1269-1284 (2013).
18. Pattingre, S. et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122, 927-939 (2005).
19. Tang, H. et al. Decreased mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis. EBioMedicine 2, 255-263 (2015).
20. Lan, Y. Y., Londono, D., Bouley, R., Rooney, M. S. & Hacohen, N. Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy. Cell Rep. 9, 180-192 (2014).
21. Griffin, L. M., Cicchini, L. & Pyeon, D. Human papillomavirus infection is inhibited by host autophagy in primary human keratinocytes. Virology 437, 12-19 (2013).
22. Salemi, S., Yousefi, S., Constantinescu, M. A., Fey, M. F. & Simon, H. U. Autophagy is required for self-renewal and differentiation of adult human stem cells. Cell Res. 22, 432-435 (2012).
23. Young, A. R. et al. Autophagy mediates the mitotic senescence transition. Genes Dev. 23, 798-803 (2009).
24. Goussetis, D. J. et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood 120, 3555-3562 (2012).
25. Guo, J. Y., Xia, B. & White, E. Autophagy-mediated tumor promotion. Cell 155, 1216-1219 (2013).
26. Peng, Y. F. et al. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. Autophagy 9, 2056-2068 (2013).
27. Gong, C. et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/ progenitor cells. Oncogene 32, 2261-2272 (2013).
28. Baginska, J. et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc. Natl Acad. Sci. USA 110, 17450-17455 (2013).
29. Messai, Y. et al. ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy. Cancer Res. 74, 6820-6832 (2014).
30. Sousa, C. M. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479-483 (2016).
31. Ma, Y., Galluzzi, L., Zitvogel, L. & Kroemer, G. Autophagy and cellular immune responses. Immunity 39, 211-227 (2013).
32. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. http://dx.doi.org/ 10.1038/nri.2016.107 (2016).
33. Shi, C. S. et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 13, 255-263 (2012).
34. Zitvogel, L., Kepp, O., Galluzzi, L. & Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13, 343-351 (2012).
35. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
36. Li, Y. et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 68, 6889-6895 (2008).
37. Pua, H. H., Dzhagalov, I., Chuck, M., Mizushima, N. & He, Y. W. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J. Exp. Med. 204, 25-31 (2007).
38. Puleston, D. J. et al. Autophagy is a critical regulator of memory CD8+ T cell formation. eLife 3, e03706 (2014).
39. Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573-1577 (2011).
40. Thorburn, J. et al. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 16, 175-183 (2009).
41. Tang, D. et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29, 5299-5310 (2010).
42. Tang, D. et al. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190, 881-892 (2010).
43. Hou, W. et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis. 4, e966 (2013).
44. Zhang, Q., Kang, R., Zeh, H. J. III, Lotze, M. T. & Tang, D. DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy 9, 451-458 (2013).
45. Garg, A. D. et al. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 9, 1292-1307 (2013).
46. Li, W. et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem. Pharmacol. 81, 1152-1163 (2011).
47. Wei, H. et al. Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev. 25, 1510-1527 (2011).
48. McAfee, Q. et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc. Natl Acad. Sci. USA 109, 8253-8258 (2012).
49. Yang, A. et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 4, 905-913 (2014).
50. Li, J., Hou, N., Faried, A., Tsutsumi, S. & Kuwano, H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur. J. Cancer 46, 1900-1909 (2010).
51. Zhao, X. G. et al. Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal carcinoma in xenograft mice. PLoS ONE 10, e0126147 (2015).
52. Golden, E. B. et al. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Neurosurg. Focus 37, E12 (2014).
53. Pan, Y. et al. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin. Cancer Res. 17, 3248-3258 (2011).
54. Chittaranjan, S. et al. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and-resistant triple-negative breast cancer. Clin. Cancer Res. 20, 3159-3173 (2014).
55. Lefort, S. et al. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy 10, 2122-2142 (2014).
56. Amaravadi, R. K. et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. 117, 326-336 (2007).
57. Dragowska, W. H. et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS ONE 8, e76503 (2013).
58. Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A. & O'Dwyer, P. J. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin. Cancer Res. 19, 2995-3007 (2013).
59. Lin, J. et al. Inhibition of autophagy enhances the anticancer activity of silver nanoparticles. Autophagy 10, 2006-2020 (2014).
60. Wei, M. F. et al. Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cells. Autophagy 10, 1179-1192 (2014).
61. Tseng, H. C. et al. Sensitizing effect of 3-methyladenine on radiation-induced cytotoxicity in radio-resistant HepG2 cells in vitro and in tumor xenografts. Chem. Biol. Interact. 192, 201-208 (2011).
62. Chen, Y. et al. Combining radiation with autophagy inhibition enhances suppression of tumor growth and angiogenesis in esophageal cancer. Mol. Med. Rep. 12, 1645-1652 (2015).
63. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690-714 (2015).
64. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1-222 (2016).
65. Maes, H. et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 26, 190-206 (2014).
66. Maycotte, P. et al. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 8, 200-212 (2012).
67. Taherian, E., Rao, A., Malemud, C. J. & Askari, A. D. The biological and clinical activity of anti-malarial drugs in autoimmune disorders. Curr. Rheumatol. Rev. 9, 45-62 (2013).
68. Piconi, S. et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 118, 3263-3272 (2011).
69. Gostner, J. M. et al. Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC. FEBS Open Bio 2, 241-245 (2012).
70. Martinson, J. A. et al. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob. Agents Chemother. 54, 871-881 (2010).
71. Akin, D. et al. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy 10, 2021-2035 (2014).
72. Mohan, N., Chakrabarti, M., Banik, N. L. & Ray, S. K. Combination of LC3 shRNA plasmid transfection and genistein treatment inhibited autophagy and increased apoptosis in malignant neuroblastoma in cell culture and animal models. PLoS ONE 8, e78958 (2013).
73. Hu, Y. L. et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 72, 1773-1783 (2012).
74. Ko, A. et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ. 21, 92-99 (2014).
75. Karsli-Uzunbas, G. et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov. 4, 914-927 (2014).
76. Kuma, A. et al. The role of autophagy during the early neonatal starvation period. Nature 432, 1032-1036 (2004).
77. Rosenfeldt, M. T. et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 504, 296-300 (2013).
78. Pietrocola, F. et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 30, 147-160 (2016).
79. Rao, S. et al. A dual role for autophagy in a murine model of lung cancer. Nat. Commun. 5, 3056 (2014).
80. Strohecker, A. M. et al. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 3, 1272-1285 (2013).
81. Guo, J. Y. et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27, 1447-1461 (2013).
82. Wolpin, B. M. et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 19, 637-638 (2014).
83. Rangwala, R. et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10, 1369-1379 (2014).
84. Mahalingam, D. et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10, 1403-1414 (2014).
85. Vogl, D. T. et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10, 1380-1390 (2014).
86. Goldberg, S. B. et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J. Thorac Oncol. 7, 1602-1608 (2012).
87. Rosenfeld, M. R. et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10, 1359-1368 (2014).
88. Rojas-Puentes, L. L. et al. Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat. Oncol. 8, 209 (2013).
89. Rangwala, R. et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10, 1391-1402 (2014).
90. Chi, K. H. et al. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort. Oncotarget 6, 16735-16745 (2015).
91. Michaud, M. et al. An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology 3, e944047 (2014).
92. Lee, C. et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl Med. 4, 124ra127 (2012).
93. Saleh, A. D. et al. Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle 12, 1955-1963 (2013).
94. Simone, B. A. et al. Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. Cell Cycle 15, 2265-2274 (2016).
95. Di Biase, S. et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell 30, 136-146 (2016).
96. Marino, G. et al. Regulation of autophagy by cytosolic acetyl-coenzyme A. Mol. Cell 53, 710-725 (2014).
97. Xia, Z. W. et al. Heme oxygenase-1-mediated CD4+CD25high regulatory T cells suppress allergic airway inflammation. J. Immunol. 177, 5936-5945 (2006).
98. Otterbein, L. E. et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6, 422-428 (2000).
99. Zhu, X. F. et al. Knockdown of heme oxygenase-1 promotes apoptosis and autophagy and enhances the cytotoxicity of doxorubicin in breast cancer cells. Oncol. Lett. 10, 2974-2980 (2015).
100. Yang, M. et al. Autophagy-based survival prognosis in human colorectal carcinoma. Oncotarget 6, 7084-7103 (2015).
101. Jung, G. et al. Autophagic markers BECLIN 1 and LC3 are associated with prognosis of multiple myeloma. Acta Haematol. 134, 17-24 (2015).
102. Ladoire, S. et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy 11, 1878-1890 (2015).
103. Ladoire, S. et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy 12, 864-875 (2016).
104. Rubinsztein, D. C., Codogno, P. & Levine, B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11, 709-730 (2012).
105. Galluzzi, L., Lopez-Soto, A., Kumar, S. & Kroemer, G. Caspases connect cell-death signaling to organismal homeostasis. Immunity 44, 221-231 (2016).
106. Lopez-Otin, C., Galluzzi, L., Freije, J. M., Madeo, F. & Kroemer, G. Metabolic control of longevity. Cell 166, 802-821 (2016).
107. de Groot, S. et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer 15, 652 (2015).
108. Argiles, J. M., Busquets, S., Stemmler, B. & Lopez-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754-762 (2014).
109. Tardif, N., Klaude, M., Lundell, L., Thorell, A. & Rooyackers, O. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am. J. Clin. Nutr. 98, 1485-1492 (2013).
110. Pigna, E. et al. Aerobic exercise and pharmacological treatments counteract cachexia by modulating autophagy in colon cancer. Sci. Rep. 6, 26991 (2016).
111. Golden, E. B. et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3, e28518 (2014).
112. Demaria, S. & Formenti, S. C. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front. Oncol. 2, 153 (2012).
113. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
114. Galluzzi, L. et al. Classification of current anticancer immunotherapies. Oncotarget 5, 12472-12508 (2014).
115. Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205-214 (2015).
116. Yang, S. et al. Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation. Cancer Immunol. Res. 4, 520-530 (2016).
117. Liang, X. et al. Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res. 72, 2791-2801 (2012).
118. Noman, M. Z. et al. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res. 71, 5976-5986 (2011).
119. Koks, C. A. et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int. J. Cancer 136, E313-E325 (2015).
120. Martinez-Outschoorn, U. E., Peiris-Pages, M., Pestell, R. G., Sotgia, F. & Lisanti, M. P. Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2016.60 (2016).
121. Guido, C. et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle 11, 3019-3035 (2012).
122. Voron, T. et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 212, 139-148 (2015).